Innovative Bedside Test Achieves Over 90% Accuracy in Sepsis Prediction
New portable blood test leveraging AI achieves over 90% accuracy in early sepsis detection, enabling faster treatment and improved patient outcomes.
Researchers from the University of British Columbia have developed a groundbreaking blood test and portable device that significantly accelerates the detection of sepsis, a life-threatening response to infection. Published in Nature Communications, this new test demonstrates an accuracy rate exceeding 90% in identifying patients at high risk of developing sepsis, marking a major advance in critical care diagnostics.
Sepsis accounts for approximately 20% of all deaths worldwide, underscoring the urgency for rapid detection methods. Traditionally, diagnosing sepsis can take up to 18 hours, often requiring specialized laboratory facilities, which delays treatment and increases mortality risk. The new approach utilizes machine learning algorithms analyzing blood samples to predict sepsis before clinical symptoms fully manifest.
In a study involving over 3,000 hospital patients with suspected sepsis, researchers identified a six-gene expression signature, called "Sepset," which reliably predicted the onset of sepsis nine times out of ten. Combining this gene signature with Reverse Transcription Polymerase Chain Reaction (RT-PCR), the test achieved 94% accuracy in early detection, allowing for quicker intervention.
To bring this technology closer to bedside use, the National Research Council of Canada (NRC) developed PowerBlade, a portable device that uses a tiny blood sample and automated process to detect sepsis swiftly. In trials with 30 patients, PowerBlade demonstrated 92% accuracy in identifying high-risk individuals and 89% in ruling out low-risk patients, providing results in under three hours. This rapid turnaround could revolutionize emergency care and remote healthcare settings.
The interdisciplinary collaboration behind this innovation integrates advances in microfluidics, engineering, and biology, enabling accessible and portable diagnostics. The Sepset testing platform is currently under commercial development, promising to empower clinicians with early warning tools and improve patient outcomes.
These advancements highlight the vital role of artificial intelligence and microfluidic technology in transforming critical care diagnostics and offering hope for reducing sepsis-related mortality worldwide. Source: medicalxpress.com
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Addressing Knowledge Gaps in Perinatal Palliative Care Amidst Changing Abortion Laws
A new review reveals significant gaps in the evidence supporting perinatal palliative care in the U.S., emphasizing the need for more research amidst increasing legal restrictions on abortion.
Scientists Question the Safety of a Promising New Anticancer Drug
Recent scientific findings challenge the safety and purity of a promising gold-based anticancer treatment, emphasizing the need for further safety evaluations due to the complex mixture of compounds produced during synthesis.
Many Physicians Would Consider Assisted Dying for Themselves in Cases of Advanced Illness
An international survey shows that over half of doctors would consider assisted dying if faced with advanced cancer or Alzheimer's, influenced by legislation and personal beliefs.